CXCL12 and CXCR4 as Potential Early Biomarkers for Luminal A and Luminal B Subtypes of Breast Cancer
Open Access
- 4 July 2023
- journal article
- research article
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 15, 573-589
Abstract
Purpose: Breast cancer is the most common type of malignancy in women. Factors that increase the risk of occurrence include chronic inflammation, with chemokines as its mediators. Therefore, the purpose of the present study was to determine the diagnostic utility of CXCL12 and CXCR4 as modern tumor markers in patients with early-stage luminal A and luminal B subtype of breast cancer and also to compare the results with the routinely used marker – CA 15-3. Patients and Methods: The study included 100 patients with early breast cancer of luminal A and B subtypes, 50 women with benign breast lesion and 50 healthy women. The levels of CXCL12 and CXCR4 concentrations were determined by enzyme-linked immunosorbent assay (ELISA), comparative marker CA 15-3 – by electrochemiluminescence method (ECLIA). Results: Concentrations of CXCL12 were significantly lower, while CXCR4 and CA 15-3 – significantly higher among patients with early-stage breast cancer than healthy women. CXCL12 also showed lower concentrations among fibroadenoma patients in comparison to healthy women, while CXCR4 – lower concentrations among fibroadenoma patients than cancer group. CXCL12 showed significantly higher values of sensitivity (79%), specificity (82%), positive predictive value (89.72%), negative predictive value (80%), diagnostic accuracy (80%) and diagnostic power (AUC = 0.8196) in the whole breast cancer group compared to the CA 15-3 marker (58%; 72%; 80.56%; 46.15%, 62.67%, 0.6434, resp.). Analysis of combined parameters resulted in increased sensitivity, negative predictive value and power of the test with a slight decrease in positive predictive value and a more significant decrease in specificity, reaching the best values for the three-parameter test CXCL12+CXCR4+CA15-3 (96%; 85.71%; AUC = 0.8812; 78.69%; 48%, resp.). Conclusion: The results indicate the preliminary usefulness of CXCL12 and CXCR4 as early biomarkers in the diagnosis of breast cancer, especially in the combined panel with CA 15-3.Keywords
This publication has 43 references indexed in Scilit:
- The Serum Concentrations of Chemokine CXCL12 and Its Specific Receptor CXCR4 in Patients with Esophageal CancerDisease Markers, 2016
- Prognostic significance of CXCL12, CXCR4, and CXCR7 in patients with breast cancer.2015
- SDF-1alpha concentration dependent modulation of RhoA and Rac1 modifies breast cancer and stromal cells interactionBMC Cancer, 2015
- ANGPTL2 increases bone metastasis of breast cancer cells through enhancing CXCR4 signalingScientific Reports, 2015
- CXCL12-CXCR4 axis promotes the natural selection of breast cancer cell metastasisTumor Biology, 2014
- Prognostic Role of C-Reactive Protein in Breast Cancer: A Systematic Review and Meta-AnalysisThe International Journal of Biological Markers, 2011
- CXCL12 expression by healthy and malignant ovarian epithelial cellsBMC Cancer, 2011
- CA 15-3: Uses and limitation as a biomarker for breast cancerClinica Chimica Acta, 2010
- CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of disease-free and overall survivalEuropean Journal of Cancer, 2009
- NF-κ B Promotes Breast Cancer Cell Migration and Metastasis by Inducing the Expression of the Chemokine Receptor CXCR4Journal of Biological Chemistry, 2003